Read by QxMD icon Read

breast cancer and adjuvance

Jian-Heng Peng, Xiao-Lin Wang, Liang Ran, Jun-Long Song, Zhi-Ting Zhang, Xin Liu, Hong-Yuan Li
This study aimed to investigate the effect of inhibiting the Notch signaling pathway on the radiosensitivity of breast cancer cells. Human breast cancer cell lines (MCF-7 and T47D) were selected and treated with radiation of different doses. Cells were treated with Gamma secretase inhibitor (GSI) to analyze the effects of GSI on the Notch signaling, which were detected by Immunofluorescence assay, RT-qPCR, and Western blot analysis. Besides, Transwell assay, Scratch test, colony formation assay, MTT assay, and flow cytometry were conducted to show the effects of GSI on the invasion and migration, survival fraction, cell viability, and apoptosis of MCF-7 and T47D cells after radiation therapy...
June 15, 2018: Journal of Cellular Biochemistry
Apar Gupta, Nisha Ohri, Bruce G Haffty
The standard treatment for early-stage breast cancer is breast conservation therapy, consisting of breast conserving surgery followed by adjuvant radiation treatment (RT). Conventionally-fractionated whole breast irradiation (CF-WBI) has been the standard RT regimen, but recently shorter courses of hypofractionated whole breast irradiation (HF-WBI) have been advocated for patient convenience and reduction in healthcare costs and resources. Areas covered: This review covers the major randomized European and Canadian trials comparing HF-WBI to CF-WBI with long-term follow-up, as well as additional recently closed randomized trials that further seek to define the applicability of HF-WBI in clinical practice...
June 14, 2018: Expert Review of Anticancer Therapy
Vered Stearns, Ben Ho Park
No abstract text is available yet for this article.
June 14, 2018: JAMA Oncology
Stephen J Luen, Rebecca Asher, Chee Khoon Lee, Peter Savas, Roswitha Kammler, Patrizia Dell'Orto, Olivia Maria Biasi, David Demanse, Lellean JeBailey, Sinead Dolan, Wolfgang Hackl, Beat Thuerlimann, Giuseppe Viale, Marco Colleoni, Meredith M Regan, Sherene Loi
Importance: A range of somatic driver alterations has been described in estrogen receptor-positive, HER2-negative (ER+/HER2-) early breast cancer (BC); however, the clinical relevance is unknown. Objective: To investigate associations of driver alterations with prognosis and the role of PIK3CA mutations in prediction of benefit associated with endocrine therapy in postmenopausal patients with ER+/HER2- early BC treated with tamoxifen or letrozole. Design, Setting, and Participants: The Breast International Group (BIG) 1-98 trial randomized 8010 postmenopausal patients with hormone receptor-positive, operable, invasive BC to monotherapy with letrozole, tamoxifen, or a sequential strategy for 5 years...
June 14, 2018: JAMA Oncology
Fiorella Vanderhoeven, Analía Lourdes Redondo, Ana Laura Martinez, Laura María Vargas-Roig, Angel Matias Sanchez, Marina Inés Flamini
Breast cancer can be classified into molecular subtypes. Tumors overexpressing HER2 protein are more aggressive and metastatic; hence, patients have a poor prognosis. Anti-HER2 strategies, such as the monoclonal antibody Trastuzumab (Tz), have therefore been developed. Despite this progress, not all patients respond to the treatment. Retinoic acid (RA) has been proposed as an adjuvant treatment of breast carcinoma because of its ability to inhibit cell growth. We evaluated the effect of Tz in combination with RA on the viability, adhesion, migration, invasion and expression of migration-related proteins in SKBR3 and BT-474 human breast cancer cells...
May 29, 2018: Oncotarget
Nadine Norton, Nicholas Fox, Christie-Ann McCarl, Kathleen S Tenner, Karla Ballman, Courtney L Erskine, Brian M Necela, Donald Northfelt, Winston W Tan, Carmen Calfa, Mark Pegram, Gerardo Colon-Otero, Edith A Perez, Raphael Clynes, Keith L Knutson
BACKGROUND: Resected HER2 breast cancer patients treated with adjuvant trastuzumab and chemotherapy have superior survival compared to patients treated with chemotherapy alone. We previously showed that trastuzumab and chemotherapy induce HER2-specific antibodies which correlate with improved survival in HER2 metastatic breast cancer patients. It remains unclear whether the generation of immunity required trastuzumab and whether endogenous antibody immunity is associated with improved disease-free survival in the adjuvant setting...
June 14, 2018: Breast Cancer Research: BCR
Xuesong Han, Jingxuan Zhao, Kathryn J Ruddy, Chun Chieh Lin, Helmneh M Sineshaw, Ahmedin Jemal
INTRODUCTION: Breast cancer in young women tends to be more aggressive, but timely treatment may not be always available, particularly to those without health insurance. We aim to examine whether the dependent coverage expansion under the Affordable Care Act (ACA-DCE) implemented in 2010 was associated with changes in time to treatment among women diagnosed with early stage breast cancer. METHODS: A total of 7,176 patients diagnosed with early stage breast cancer in 2007-2009 (pre-ACA) and 2011-2013 (post-ACA) were identified from the National Cancer Database...
2018: PloS One
Aude Thouvenot, Yasmine Bizet, Laurent S Baccar, Michele Lamuraglia
Metastasis of non-gynaecological tumours to the cervix is a rare event, and metastasis from breast cancer is even rarer, with only a limited number of such cases reported in the literature to date. We herein report the case of an 86-year-old female patient who had undergone mastectomy and axillary lymphadenectomy for invasive ductal cell breast carcinoma 2 years prior, followed by adjuvant hormonal therapy with letrozole. During hospitalization for anemia associated with an inflammatory syndrome and abdominal pain with menorrhagia, an abdominal ultrasound examination revealed a suspicious uterine mass with irregular contours and abnormal vascularization with associated increase of the blood level of cancer antigen 15-3 to 34 kU/l...
July 2018: Molecular and Clinical Oncology
Karen A Cadoo, Peter A Kaufman, Andrew D Seidman, Cassandra Chang, Dongyuan Xing, Tiffany A Traina
BACKGROUND: Eribulin has significantly improved overall survival for patients with metastatic breast cancer who received ≥ 2 prior chemotherapy regimens for advanced disease. This trial assessed eribulin as adjuvant therapy for patients with early-stage breast cancer. PATIENTS AND METHODS: Patients with human epidermal growth factor receptor 2-negative, stage I to III breast cancer received doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 provided intravenously on day 1 of each 14-day cycle for 4 cycles, with pegfilgrastim on day 2, followed by 4 cycles of eribulin mesylate 1...
April 7, 2018: Clinical Breast Cancer
Piotr Pluta, Dorota Jesionek-Kupnicka, Joanna Kubicka-Wołkowska, Agnieszka Pluta, Kamil Brzozowski, Piotr Potemski, Janusz Piekarski, Radzisław Kordek, Arkadiusz Jeziorski
Preoperative systemic therapy including neoadjuvant chemotherapy (NCT) is standard treatment in locally advanced breast cancer (LABC), the aim of which is to enable a radical surgery and to reduce the risk of local and distant recurrence. It has been established that NCT in LABC may effectively induce apoptosis. The study objective was to assess the role of a proapoptotic second mitochondria-derived activator of apoptosis (SMAC) in LABC. The study group comprised 56 patients with advanced non-metastatic breast cancer (stage IIB -node positive and III), who received NCT followed by surgery and adjuvant treatment...
2018: Polish Journal of Pathology: Official Journal of the Polish Society of Pathologists
M Ignatiadis, S Litière, F Rothe, S Riethdorf, C Proudhon, T Fehm, K Aalders, H Forstbauer, P Fasching, E Brain, P Vuylsteke, E Guardiola, R Lorenz, K Pantel, K Tryfonidis, W Janni, M Piccart, C Sotiriou, B Rack, J-Y Pierga
Background: Trastuzumab improves the outcome of women with HER2 positive breast cancer. We aimed to assess whether trastuzumab decreases the detection rate of Circulating Tumor Cells (CTCs) in women with high risk, HER2 non-amplified, early breast cancer. Patients and Methods: The EORTC 90091-10093 BIG 1-12 Treat CTC is a phase 2 trial, conducted in 70 hospitals and 6 CTC laboratories across 5 European countries. Patients with centrally confirmed HER2 non-amplified breast cancer and ≥1 centrally confirmed CTC per 15mL of blood by CellSearch® following surgery and (neo)adjuvant chemotherapy were randomized (1:1) to 6 cycles of trastuzumab intravenously versus 18 weeks of observation...
June 11, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
Turkan Ozturk Topcu, Feyyaz Ozdemir, Halil Kavgaci, Meral Gunaldi, Hakan Kocoglu, Goksen Inanc Imamoglu, Ahmet Mentese, Serap Ozer Yaman, Asim Orem, Fazil Aydin
Introduction: Breast cancer mortality rates after metastasis is high. Urokinase plasminogen activator receptor (uPAR) and carbonic anhydrase IX (CAIX) play very important roles during tumor cell invasion and metastasis. The purpose of this study was to evaluate plasma levels of uPAR and CAIX and the effect of anthracycline-based chemotherapy on these biomarkers in patients with operable breast cancer. Materials and Methods: Sixty-five patients and 25 age-matched healthy controls were enrolled...
April 2018: Journal of Cancer Research and Therapeutics
Nisha Marwah, Ashima Batra, Sanjay Marwah, Veena Gupta, Samta Shakya, Rajeev Sen
Aim: Routine assessment of cell proliferation is recommended in the pathologic evaluation for all breast cancers. Considering the poor reproducibility and interobserver variability in mitotic counts, Ki-67 is an easily available and reliable substitute for mitotic counts and has been shown to have a significant relationship with the histologic grade of malignancy and the mitotic activity of tumors. Our study aimed at exploring Ki-67 expression and studying its correlation with other established prognostic parameters...
April 2018: Journal of Cancer Research and Therapeutics
Traci LeMasters, S Suresh Madhavan, Usha Sambamoorthi, Hannah W Hazard-Jenkins, Kimberly M Kelly, Dustin Long
Background: This study examined receipt of guideline-concordant care (GCC) according to evidence-based treatment guidelines and quality measures and specific types of treatment among older women with breast cancer. Patients and Methods: A total of 142,433 patients aged ≥66 years diagnosed with stage I-III breast cancer between 2007 and 2011 were identified in the SEER-Medicare linked database. Algorithms considering cancer characteristics and the appropriate course of care as per guidelines versus actual care received determined receipt of GCC...
June 2018: Journal of the National Comprehensive Cancer Network: JNCCN
Anishka D'Souza, Darcy Spicer, Janice Lu
Endocrine therapy has historically formed the basis of treatment of metastatic hormone receptor-positive breast cancer. The development of endocrine resistance has led to the development of newer endocrine drug combinations. Use of the CDK4/6 inhibitors has significantly improved progression-free survival in this group of patients. There are multiple studies of the use of P13K inhibitors and mTOR inhibitors for use as subsequent lines of therapy, particularly for endocrine resistance. The optimal sequencing of therapy should be based on medical comorbidities, prior adjuvant therapies, quality of life, side-effect profile, and disease-free interval...
June 11, 2018: Journal of Hematology & Oncology
Brittany Humphries, Stéphanie Collins, Laurence Guillaumie, Julie Lemieux, Anne Dionne, Louise Provencher, Jocelyne Moisan, Sophie Lauzier
Adjuvant endocrine therapy (AET) taken for a minimum of five years reduces the recurrence and mortality risks among women with hormone-sensitive breast cancer. However, adherence to AET is suboptimal. To guide the development of theory-based interventions to enhance AET adherence, we conducted a study to explore beliefs regarding early adherence to AET. This qualitative study was guided by the Theory of Planned Behavior (TPB). We conducted focus groups and individual interviews among women prescribed AET in the last two years ( n = 43)...
June 9, 2018: Pharmacy (Basel, Switzerland)
Fady B Geara, Toufic Eid, Nicolas Zouain, Ranim Thebian, Therese Andraos, Chirine Chehab, Paul Ramia, Bassem Youssef, Youssef H Zeidan
PURPOSE: Acute radiation dermatitis is a common side-effect of radiotherapy in breast cancer and has a profound impact on patients' quality of life, due to pain and discomfort. The aim of this study is to compare the effect of β-sitosterol (Mebo) ointment to trolamine (Biafine) cream for the prevention and treatment of radiation dermatitis in breast cancer patients receiving adjuvant radiation therapy. MATERIALS AND METHODS: This is a prospective open-label randomized phase III study developed to assess the efficacy of 2 topical agents used for management of acute radiation dermatitis...
June 7, 2018: American Journal of Clinical Oncology
Elie El Rassy, Marwan Ghosn, Fadi Farhat, Ziad Bakouny, Tarek Assi, Georges Chahine, Fadi Nasr, Fady Ghassan Haddad, Fadi El Karak, Joseph Kattan
Background: The present study reports on the efficacy and safety of adjuvant docetaxel in real-life patients with early-stage breast cancer. Methods: This is a prospective, multicenter, post-marketing study that evaluates the efficacy and safety of docetaxel-based regimens in patients with early breast cancer treated between 2007 and 2012. Results: A total of 698 female breast cancer patients receiving adjuvant docetaxel-based regimens were included in this study...
April 2018: Breast Care
Stefania Gori, Fabio Puglisi, Michela Cinquini, Giovanni Pappagallo, Antonio Frassoldati, Laura Biganzoli, Laura Cortesi, Alba Fiorentino, Catia Angiolini, Corrado Tinterri, Andrea De Censi, Alessia Levaggi, Lucia Del Mastro
Premenopausal women with hormone receptor-positive early breast cancer are candidates for adjuvant endocrine therapy, as recommended by the major international guidelines. To date, adjuvant endocrine options for premenopausal women include tamoxifen with or without ovarian function suppression (OFS) or an aromatase inhibitor with OFS. Multiple strategies for endocrine treatment of premenopausal women with hormone-responsive breast cancer have been assessed, and the results of randomised clinical trials have been reported over the last years...
June 7, 2018: European Journal of Cancer
Daniel Rayson, Jennifer I Payne, James C R Michael, Kaitlyn M Tsuruda, Mohamed Abdolell, Penny J Barnes
BACKGROUND: Most investigations have compared triple-negative breast cancer (TNBC) to non-TNBC to elucidate clinical or epidemiologic differences between subtypes. We examined a contemporary cohort of patients with primary TNBC by detection and age at diagnosis within a population-based breast screening program to examine survival outcomes. PATIENTS AND METHODS: All women with a diagnosis of primary TNBC between January 1, 2005, and December 31, 2012, in Nova Scotia, Canada, were included...
April 28, 2018: Clinical Breast Cancer
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"